These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9613756)

  • 41. Long-term treatment of restless legs syndrome with dopamine agonists.
    Ondo W; Romanyshyn J; Vuong KD; Lai D
    Arch Neurol; 2004 Sep; 61(9):1393-7. PubMed ID: 15364685
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Validation of the "L-DOPA test" for diagnosis of restless legs syndrome.
    Stiasny-Kolster K; Kohnen R; Möller JC; Trenkwalder C; Oertel WH
    Mov Disord; 2006 Sep; 21(9):1333-9. PubMed ID: 16705685
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Pergolide: a useful agonist for the treatment of Parkinson disease].
    Bonnet AM; Houeto JL
    Rev Neurol (Paris); 2002 Jul; 158(6-7):744-5. PubMed ID: 12486908
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of restless legs syndrome after dopaminergic treatment in a patient with periodic leg movements in sleep.
    Santamaria J; Iranzo A; Tolosa E
    Sleep Med; 2003 Mar; 4(2):153-5. PubMed ID: 14592347
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term effects of pergolide in the treatment of restless legs syndrome.
    Stiasny K; Wetter TC; Winkelmann J; Brandenburg U; Penzel T; Rubin M; Hundemer HP; Oertel WH; Trenkwalder C
    Neurology; 2001 May; 56(10):1399-402. PubMed ID: 11376198
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dopaminergic augmentation of restless legs syndrome.
    García-Borreguero D; Williams AM
    Sleep Med Rev; 2010 Oct; 14(5):339-46. PubMed ID: 20219397
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pergolide and Parkinson's disease: new preparation. No clear benefit.
    Prescrire Int; 2000 Dec; 9(50):177-9. PubMed ID: 11475497
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Restless legs syndrome in Parkinson's disease.
    Gómez-Esteban JC; Zarranz JJ; Tijero B; Velasco F; Barcena J; Rouco I; Lezcano E; Lachen MC; Jauregui A; Ugarte A
    Mov Disord; 2007 Oct; 22(13):1912-6. PubMed ID: 17579369
    [TBL] [Abstract][Full Text] [Related]  

  • 49. First night efficacy of pramipexole in restless legs syndrome and periodic leg movements.
    Manconi M; Ferri R; Zucconi M; Oldani A; Fantini ML; Castronovo V; Ferini-Strambi L
    Sleep Med; 2007 Aug; 8(5):491-7. PubMed ID: 17512780
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pergolide in the management of restless legs syndrome: an extended study.
    Silber MH; Shepard JW; Wisbey JA
    Sleep; 1997 Oct; 20(10):878-82. PubMed ID: 9415948
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gabapentin enacarbil, a gabapentin prodrug for the treatment of the neurological symptoms associated with disorders such as restless legs syndrome.
    Merlino G; Serafini A; Young JJ; Robiony F; Gigli GL; Valente M
    Curr Opin Investig Drugs; 2009 Jan; 10(1):91-102. PubMed ID: 19127491
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Restless legs. A much neglected syndrome].
    Ulfberg J; Jönsson R; Lindberg E; Nyström B; Mallon L
    Lakartidningen; 1999 Mar; 96(10):1183-4, 1187-8. PubMed ID: 10193123
    [TBL] [Abstract][Full Text] [Related]  

  • 53. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome.
    Oertel WH; Trenkwalder C; Zucconi M; Benes H; Borreguero DG; Bassetti C; Partinen M; Ferini-Strambi L; Stiasny-Kolster K
    Mov Disord; 2007; 22 Suppl 18():S466-75. PubMed ID: 17516455
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
    Enomoto M; Inoue Y; Namba K; Munezawa T; Matsuura M
    Mov Disord; 2008 Apr; 23(6):811-6; quiz 926. PubMed ID: 18074382
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome.
    Silver N; Allen RP; Senerth J; Earley CJ
    Sleep Med; 2011 May; 12(5):440-4. PubMed ID: 21239226
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of pergolide on restless legs and leg movements in sleep in uremic patients.
    Pieta J; Millar T; Zacharias J; Fine A; Kryger M
    Sleep; 1998 Sep; 21(6):617-22. PubMed ID: 9779521
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A controlled study of additional sr-L-dopa in L-dopa-responsive restless legs syndrome with late-night symptoms.
    Collado-Seidel V; Kazenwadel J; Wetter TC; Kohnen R; Winkelmann J; Selzer R; Oertel WH; Trenkwalder C
    Neurology; 1999 Jan; 52(2):285-90. PubMed ID: 9932945
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Systematic evaluation of augmentation during treatment with ropinirole in restless legs syndrome (Willis-Ekbom disease): results from a prospective, multicenter study over 66 weeks.
    García-Borreguero D; Högl B; Ferini-Strambi L; Winkelman J; Hill-Zabala C; Asgharian A; Allen R
    Mov Disord; 2012 Feb; 27(2):277-83. PubMed ID: 22328464
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Quick titration of pergolide in cotreatment with domperidone is safe and effective.
    Jansen PA; Herings RM; Samson MM; De Vreede PL; Schuurmans-Daemen LM; Hovestadt A; Verhaar HJ; Van Laar T
    Clin Neuropharmacol; 2001; 24(3):177-80. PubMed ID: 11391131
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Levodopa for idiopathic restless legs syndrome: evidence-based review.
    Conti CF; de Oliveira MM; Andriolo RB; Saconato H; Atallah AN; Valbuza JS; Coin de Carvalho LB; do Prado GF
    Mov Disord; 2007 Oct; 22(13):1943-51. PubMed ID: 17659645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.